Search
-
Hemostemix Submits Its Retrospective Heart Study to Leading Stem Cell Journal and Has Prepared Its CLI Phase II Clinical Trial Manuscript for Peer Review
August 8, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it…
-
Hemostemix Closes $403,539 of the Unit Private Placement
June 28, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce it…
-
Hemostemix’s Private Placement Use of Proceeds
June 21, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce the…
-
Hemostemix Announces Unit Private Placement
June 1, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce a…
-
Dr. McNorgan Discusses Hemostemix’s Stem Cell Technology and Potential with Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Advisory Board Member Dr.…
-
Thomas Smeenk Discusses the Intersection of Hemostemix’s NCP Treatment and Elon Musk’s Neuralink
In this InvestorIntel interview, Tracy Weslosky talks with Hemostemix Inc.’s (TSXV: HEM | OTCQB: HMTXF) Co-Founder, CEO, and President…
-
Hemostemix (PreCerv Inc.) Retains Chris McNorgan PhD to License NCP-01 to Neural Electrode Brain Implant Company
May 02, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Hemostemix’ Second Round Interviews with Executive Vice President Business Development Candidates
April 03, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased…
-
Hemostemix Engages Montreal’s RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally
March 29, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is…
-
Hemostemix Closes $762,400 of The Unit Private Placement
March 21, 2023 (Source) – Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased…